000305513 001__ 305513
000305513 005__ 20251203120135.0
000305513 0247_ $$2doi$$a10.1002/hed.70070
000305513 0247_ $$2pmid$$apmid:41122870
000305513 0247_ $$2ISSN$$a1043-3074
000305513 0247_ $$2ISSN$$a0148-6403
000305513 0247_ $$2ISSN$$a1097-0347
000305513 0247_ $$2ISSN$$a1930-2398
000305513 037__ $$aDKFZ-2025-02197
000305513 041__ $$aEnglish
000305513 082__ $$a610
000305513 1001_ $$00009-0004-8843-9938$$aHan, Rui$$b0
000305513 245__ $$aLoss of the Y Chromosome in Oral Potentially Premalignant Disorders Predicts Malignant Progression: An Integrative Cross-Species Multi-Cohort Bioinformatic Study.
000305513 260__ $$aNew York, NY [u.a.]$$bWiley Interscience$$c2025
000305513 3367_ $$2DRIVER$$aarticle
000305513 3367_ $$2DataCite$$aOutput Types/Journal article
000305513 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1764759660_1331671
000305513 3367_ $$2BibTeX$$aARTICLE
000305513 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000305513 3367_ $$00$$2EndNote$$aJournal Article
000305513 500__ $$a#LA:E220# / #DKFZ-MOST-Ca204# / epub 
000305513 520__ $$aThe loss of the Y chromosome (LOY) and the extreme down-regulation of Y chromosome gene expression (EDY) are frequently observed in oral squamous cell carcinoma (OSCC). However, their roles in oral potentially malignant disorders (OPMDs) are unclear.A comprehensive bioinformatic analysis was performed using publicly available datasets from chemically induced mouse OSCC models and human cohorts. The analysis included LOY/EDY detection, gene set variation analysis (GSVA), PROGENy pathway profiling, cell-to-cell communication inference, and epigenetic correlation studies.LOY was prevalent among men with OPMD, and EDY was identified in both mouse models and human OPMDs. The presence of LOY/EDY was associated with a higher risk of OPMD progression to OSCC. Single-cell analysis revealed that EDY-positive epithelial cells exhibited elevated oncogenic pathway activity and enhanced IL17-IL17RC signaling, possibly due to the loss of KDM5D in epithelial cells and altered epigenetic regulation.LOY/EDY can be detected in OPMD and promotes malignant progression by altering oncogenic signaling and epithelial cell interactions. LOY/EDY may serve as both a diagnostic biomarker and a therapeutic target, improving clinical management and patient outcomes.
000305513 536__ $$0G:(DE-HGF)POF4-315$$a315 - Bildgebung und Radioonkologie (POF4-315)$$cPOF4-315$$fPOF IV$$x0
000305513 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000305513 650_7 $$2Other$$aextreme down‐regulation of Y chromosome gene expression (EDY)
000305513 650_7 $$2Other$$aloss of the Y chromosome (LOY)
000305513 650_7 $$2Other$$alysine demethylase 5D (KDM5D)
000305513 650_7 $$2Other$$aoral potentially premalignant disorders (OPMD)
000305513 650_7 $$2Other$$aoral squamous cell carcinoma (OSCC)
000305513 7001_ $$aPoell, Jos B$$b1
000305513 7001_ $$0P:(DE-HGF)0$$aConde-Lopez, Cristina$$b2
000305513 7001_ $$aSalo, Tuula$$b3
000305513 7001_ $$0P:(DE-He78)f3723bca6eb95009d4c95a7590617b68$$aKurth, Ina$$b4$$udkfz
000305513 7001_ $$aBrakenhoff, Ruud H$$b5
000305513 7001_ $$0P:(DE-He78)2e5f34f1c58eda4787a14c9dc139ca5f$$aHess, Jochen$$b6$$eLast author$$udkfz
000305513 773__ $$0PERI:(DE-600)2001440-5$$a10.1002/hed.70070$$gp. hed.70070$$pnn$$tHead & neck$$vnn$$x1043-3074$$y2025
000305513 909CO $$ooai:inrepo02.dkfz.de:305513$$pVDB
000305513 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000305513 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)f3723bca6eb95009d4c95a7590617b68$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000305513 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)2e5f34f1c58eda4787a14c9dc139ca5f$$aDeutsches Krebsforschungszentrum$$b6$$kDKFZ
000305513 9131_ $$0G:(DE-HGF)POF4-315$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vBildgebung und Radioonkologie$$x0
000305513 9141_ $$y2025
000305513 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2024-12-18$$wger
000305513 915__ $$0StatID:(DE-HGF)3001$$2StatID$$aDEAL Wiley$$d2024-12-18$$wger
000305513 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2024-12-18
000305513 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2024-12-18
000305513 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2024-12-18
000305513 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2024-12-18
000305513 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2024-12-18
000305513 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2024-12-18
000305513 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2024-12-18
000305513 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2024-12-18
000305513 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2024-12-18
000305513 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bHEAD NECK-J SCI SPEC : 2022$$d2024-12-18
000305513 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2024-12-18
000305513 9202_ $$0I:(DE-He78)E220-20160331$$kE220$$lE220 Radioonkologie Radiobiologie$$x0
000305513 9201_ $$0I:(DE-He78)E220-20160331$$kE220$$lE220 Radioonkologie Radiobiologie$$x0
000305513 9201_ $$0I:(DE-He78)HD01-20160331$$kHD01$$lDKTK HD zentral$$x1
000305513 980__ $$ajournal
000305513 980__ $$aVDB
000305513 980__ $$aI:(DE-He78)E220-20160331
000305513 980__ $$aI:(DE-He78)HD01-20160331
000305513 980__ $$aUNRESTRICTED